T2 Biosystems named Phase 1 winner in LymeX Diagnostics Prize

T2 Biosystems announced that the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation have selected T2 Biosystems as a Phase 1 winner in the LymeX Diagnostics Prize, a LymeX Innovation Accelerator prize competition to accelerate the development of Lyme disease diagnostics. As a Phase 1 winner, T2 Biosystems will receive $100,000 and an invitation to participate in a second phase. The current two-tier serological testing system relies on the presence of antibodies and can only be used accurately four to six weeks after infection. The LymeX Diagnostics Prize’s open innovation model is accelerating discovery and development by offering no-strings-attached funding alongside exclusive access to key resources and collaboration opportunities-helping innovators take their solutions from concept to the healthcare market.